We maintain our Sell rating on GlaxoSmithKline Pharma (GSK) and revise our TP to Rs1,525 (earlier Rs1,390) based on 24x March'19E EPS of Rs63.4. GSK's Q2FY18 results exceeded our and consensus estimates. GSK revenue grew by 5%, EBIDTA margin improved 540bps to 23.0% and net profit grew 27% YoY. GSK's pharma segment grew by 6.3% during the quarter. That said, the company has a strong presence in the vaccines segment and is likely to derive growth from the same. Key risks to our assumptions include faster-thanexpected growth in the domestic market and higher growth of its flagship brands. We recommend a switch to other pharma companies, Abbott India or...